IQVIA (NYSE:IQV) Receives Outperform Rating from Leerink Partners

Leerink Partners reaffirmed their outperform rating on shares of IQVIA (NYSE:IQV) in a research report released on Tuesday morning,Benzinga reports. They currently have a $248.00 price target on the medical research company’s stock, down from their previous price target of $260.00.

Several other brokerages also recently commented on IQV. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Robert W. Baird lowered their price objective on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. Truist Financial lowered their price objective on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a research report on Monday, November 4th. TD Cowen lowered their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Argus upgraded shares of IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Stock Up 0.2 %

NYSE IQV opened at $191.33 on Tuesday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a 50 day moving average of $225.08 and a 200-day moving average of $227.79. The company has a market cap of $34.73 billion, a price-to-earnings ratio of 25.11, a PEG ratio of 1.98 and a beta of 1.51.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This represents a 6.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On IQVIA

Several institutional investors and hedge funds have recently added to or reduced their stakes in IQV. Versant Capital Management Inc increased its stake in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares during the last quarter. Opal Wealth Advisors LLC purchased a new stake in IQVIA in the 2nd quarter valued at about $27,000. Capital Performance Advisors LLP purchased a new stake in IQVIA in the 3rd quarter valued at about $27,000. Park Place Capital Corp purchased a new stake in IQVIA in the 3rd quarter valued at about $28,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in IQVIA in the 2nd quarter valued at about $29,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.